Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) (vol 43, pg 17, 2020)

被引：1
|
作者：
Patek, Taylor M. [1 ,2 ]
Teng, Chengwen [1 ,2 ]
Kennedy, Kaitlin E. [1 ,2 ]
Alvarez, Carlos A. [3 ]
Frei, Christopher R. [1 ,2 ,4 ,5 ]
机构：
[1] Univ Texas Austin, Pharmacotherapy Div, Coll Pharm, San Antonio, TX USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, Long Sch Med, 7703 Floyd Curl Dr,MSC-6220, San Antonio, TX 78229 USA
[3] Texas Tech Univ, Hlth Sci Ctr, Div Clin Translat Res, Hodge Sch Pharm, Dallas, TX USA
[4] South Texas Vet Hlth Care Syst, San Antonio, TX USA
[5] Univ Hlth Syst, San Antonio, TX USA
来源：
DRUG SAFETY | 2020年 / 43卷 / 08期
关键词：
D O I：
10.1007/s40264-020-00971-y
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
In the original publication of the article, the second sentence in the figure 2 caption should read as below:
引用
收藏
页码：825 / 825
页数：1
相关论文
共 50 条
  • [31] Evaluating Reports of Pancreatic Malignancy and Liraglutide: A Pharmacovigilance Study of the FDA Adverse Event Reporting System
    Alvarez, Carlos A.
    Teng, Chengwen
    Mansi, Ishak
    DIABETES, 2020, 69
  • [32] Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
    Ma, Pan
    Pan, Xinmei
    Liu, Ruixiang
    Qu, Ya
    Xie, Linli
    Xie, Jiangchuan
    Cao, Liya
    Chen, Yongchuan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [33] DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020
    Patrick M. Jedlowski
    Mahdieh F. Jedlowski
    Maryam T. Fazel
    American Journal of Clinical Dermatology, 2021, 22 : 891 - 900
  • [34] DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020
    Jedlowski, Patrick M.
    Jedlowski, Mahdieh F.
    Fazel, Maryam T.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (06) : 891 - 900
  • [35] Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
    Bao, Yiwen
    Chen, Jiaju
    Duan, Luting
    Wang, Fujue
    Lai, Han
    Mo, Zeming
    Zhu, Weiliang
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [36] Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
    Li, Shangze
    Huang, Runcheng
    Meng, Yuanyuan
    Liu, Yijia
    Qian, Jiao
    Zou, Junjie
    Yang, Jun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [37] A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
    Cui, Zhiwei
    Cheng, Feiyan
    Wang, Lihui
    Zou, Fan
    Pan, Rumeng
    Tian, Yuhan
    Zhang, Xiyuan
    She, Jing
    Zhang, Yidan
    Yang, Xinyuan
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [38] Postmarketing Safety of Irinotecan and Association with Pharmacogenomic Studies: a Pharmacovigilance Study Based on FDA Adverse Event Reporting System (FAERS)
    Kong, Lingti
    Rong, Li
    Qiu, Hongyu
    Xie, Mengyuan
    Xu, Jian
    LATIN AMERICAN JOURNAL OF PHARMACY, 2022, 41 (08): : 1632 - 1638
  • [39] Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
    Li, Yidan
    Sun, Shengzhu
    Wu, Hongyun
    Zhao, Leiyong
    Peng, Wei
    BMC PHARMACOLOGY & TOXICOLOGY, 2024, 25 (01):
  • [40] Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
    Sato, Kenichiro
    Mano, Tatsuo
    Iwata, Atsushi
    Toda, Tatsushi
    BIOSCIENCE TRENDS, 2020, 14 (02) : 139 - 143
12345